No Data
No Data
No Data
Sino Biopharm's New Indication Application for Combo Therapy Accepted in China
Sino Biopharmaceutical (01177.HK): The application for listing approval for the new indication of the combination of Bemarolizumab Injection and Anlotinib Hydrochloride Capsules for first-line treatment of advanced renal cell carcinoma has been accepted.
On August 1st, Gelon Hui announced that Sino Biopharmaceutical, which independently developed Innovative Drug Category 1 Pembrolizumab Injection combined with Innovative Drug Category 1 Anlotinib Hydrochloride Capsules, has submitted a new indication listing application to the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) and has been accepted, which is used for first-line treatment of advanced unresectable or metastatic renal cell carcinoma (RCC). Pembrolizumab Injection is a novel sequence innovative fully humanized Anti-PD-L1 monoclonal antibody developed by the Group, which was approved for listing by the NMPA in May 2024 and is used for
Express News | Sino Biopharmaceutical - Acceptance of New Indication Application for Marketing of Benmelstobart Injection by Nmpa
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Sino Biopharm (01177.HK) plans to hold a board of directors meeting on August 13 to approve its interim performance.
Sino Biopharm (01177.HK) announced that it will hold a board of directors meeting on Tuesday, August 13, 2024 to approve (including) the publication of unaudited interim results for the six-month period ending June 30, 2024 for the company and its subsidiaries, as well as to consider the distribution of interim dividends (if any).
SINO BIOPHARM: NOTIFICATION OF BOARD MEETING
No Data